These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 19741229)

  • 1. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
    Lindå H; von Heijne A; Major EO; Ryschkewitsch C; Berg J; Olsson T; Martin C
    N Engl J Med; 2009 Sep; 361(11):1081-7. PubMed ID: 19741229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
    Wenning W; Haghikia A; Laubenberger J; Clifford DB; Behrens PF; Chan A; Gold R
    N Engl J Med; 2009 Sep; 361(11):1075-80. PubMed ID: 19741228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.
    Van Assche G; Van Ranst M; Sciot R; Dubois B; Vermeire S; Noman M; Verbeeck J; Geboes K; Robberecht W; Rutgeerts P
    N Engl J Med; 2005 Jul; 353(4):362-8. PubMed ID: 15947080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
    Langer-Gould A; Atlas SW; Green AJ; Bollen AW; Pelletier D
    N Engl J Med; 2005 Jul; 353(4):375-81. PubMed ID: 15947078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reemergence of PML in natalizumab-treated patients--new cases, same concerns.
    Major EO
    N Engl J Med; 2009 Sep; 361(11):1041-3. PubMed ID: 19741226
    [No Abstract]   [Full Text] [Related]  

  • 6. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
    Kleinschmidt-DeMasters BK; Tyler KL
    N Engl J Med; 2005 Jul; 353(4):369-74. PubMed ID: 15947079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
    Verbeeck J; Van Assche G; Ryding J; Wollants E; Rans K; Vermeire S; Pourkarim MR; Noman M; Dillner J; Van Ranst M; Rutgeerts P
    Gut; 2008 Oct; 57(10):1393-7. PubMed ID: 18436577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    Warnke C; Adams O; Kieseier BC
    N Engl J Med; 2009 Dec; 361(25):2489; author reply 2489-90. PubMed ID: 20050216
    [No Abstract]   [Full Text] [Related]  

  • 9. A giant MS plaque mimicking PML during natalizumab treatment.
    Twyman C; Berger JR
    J Neurol Sci; 2010 Apr; 291(1-2):110-3. PubMed ID: 20144466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
    Warnke C; Adams O; Hartung HP; Kieseier BC
    Ann Neurol; 2011 Jan; 69(1):215-6; author reply 216. PubMed ID: 21280097
    [No Abstract]   [Full Text] [Related]  

  • 11. Early changes on electroencephalography in natalizumab-associated progressive multifocal leucoencephalopathy.
    Kleiter I; Schröder M; Lürding R; Schuierer G; Clifford DB; Bogdahn U; Steinbrecher A; Pöschl P
    Mult Scler; 2010 Jun; 16(6):749-53. PubMed ID: 20453014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis.
    Schröder A; Lee DH; Hellwig K; Lukas C; Linker RA; Gold R
    Arch Neurol; 2010 Nov; 67(11):1391-4. PubMed ID: 20625069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ
    Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological and clinical consequences of treating a patient with natalizumab.
    Schwab N; Höhn KG; Schneider-Hohendorf T; Metz I; Stenner MP; Jilek S; Du Pasquier RA; Gold R; Meuth SG; Ransohoff RM; Brück W; Wiendl H
    Mult Scler; 2012 Mar; 18(3):335-44. PubMed ID: 21908480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.
    Aly L; Yousef S; Schippling S; Jelcic I; Breiden P; Matschke J; Schulz R; Bofill-Mas S; Jones L; Demina V; Linnebank M; Ogg G; Girones R; Weber T; Sospedra M; Martin R
    Brain; 2011 Sep; 134(Pt 9):2687-702. PubMed ID: 21908874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    Chen Y; Bord E; Tompkins T; Miller J; Tan CS; Kinkel RP; Stein MC; Viscidi RP; Ngo LH; Koralnik IJ
    N Engl J Med; 2009 Sep; 361(11):1067-74. PubMed ID: 19741227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
    Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
    Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
    JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
    Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
    JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The human JC polyomavirus (JCPyV): virological background and clinical implications.
    Hirsch HH; Kardas P; Kranz D; Leboeuf C
    APMIS; 2013 Aug; 121(8):685-727. PubMed ID: 23781977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.